|
SLC25A44 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.0503156384375E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.25010002349768E-11 |
| Normal-vs-Stage2 |
1.784170E-04 |
| Normal-vs-Stage3 |
4.96469976241087E-10 |
| Normal-vs-Stage4 |
2.26599999875177E-08 |
| Stage1-vs-Stage2 |
2.185200E-01 |
| Stage1-vs-Stage3 |
4.887800E-01 |
| Stage1-vs-Stage4 |
3.444400E-01 |
| Stage2-vs-Stage3 |
1.321630E-01 |
| Stage2-vs-Stage4 |
1.129950E-01 |
| Stage3-vs-Stage4 |
7.106800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.90145726625724E-12 |
| Normal-vs-AfricanAmerican |
5.557500E-03 |
| Normal-vs-Asian |
3.0382000000273E-06 |
| Caucasian-vs-AfricanAmerican |
1.181180E-01 |
| Caucasian-vs-Asian |
6.494200E-01 |
| AfricanAmerican-vs-Asian |
2.891200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33599997731437E-09 |
| Normal-vs-Female |
1.00970343197559E-11 |
| Male-vs-Female |
5.653800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.28689947587191E-10 |
| Normal-vs-Age(41-60Yrs) |
2.27699969990169E-10 |
| Normal-vs-Age(61-80Yrs) |
1.77369999798671E-08 |
| Normal-vs-Age(81-100Yrs) |
5.222200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.148600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.907400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.320400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.907600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.059200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.334800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.62450000013226E-07 |
| Classical-VS-Follicular |
1.895600E-02 |
| Classical-VS-Other |
6.522200E-02 |
| Classical-VS-Normal |
3.26850002618784E-09 |
| Tall-VS-Follicular |
2.479600E-02 |
| Tall-VS-Other |
9.135200E-01 |
| Tall-VS-Normal |
1.82764914313793E-12 |
| Follicular-VS-Other |
3.502600E-01 |
| Follicular-VS-Normal |
2.05850003709429E-09 |
| Other-VS-Normal |
2.560500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.9314999013036E-10 |
| Normal-vs-N1 |
1.34720001820909E-09 |
| N0-vs-N1 |
1.096390E-01 |
|
|
